A pilot study on the immunological effects of oral administration of donor major histocompatibility complex class II peptides in renal transplant recipients

Clinical Transplantation

Volumn 22, Issue 6, 2008, Pages 754-759

  Womer, Karl L ^a,d   Magee, Colm C ^b   Najafian, Nader ^b   Vella, John P ^c   Milford, Edgar L ^b   Sayegh, Mohamed H ^b   Carpenter, Charles B ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MAINE MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

Active suppression; Chronic allograft nephropathy; Epitope spreading; Indirect allorecognition; Kidney transplantation; Oral tolerance

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; HLA DR2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ALLOIMMUNITY; ARTICLE; CASE REPORT; CHRONIC ALLOGRAFT NEPHROPATHY; COMBINATION CHEMOTHERAPY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HLA MATCHING; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; PILOT STUDY; PRIORITY JOURNAL; SENSITIZATION; T LYMPHOCYTE;

ADMINISTRATION, ORAL; CELL PROLIFERATION; CHRONIC DISEASE; GRAFT REJECTION; HLA-DR2 ANTIGEN; HUMANS; KIDNEY TRANSPLANTATION; PEPTIDE FRAGMENTS; PILOT PROJECTS; T-LYMPHOCYTES; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 56349167148     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2008.00871.x     Document Type: Article

References (28)

1. Garside P, Mowat AM. Oral tolerance. Semin Immunol 2001: 13: 177.
2. Kraus TA, Mayer L. Oral tolerance and inflammatory bowel disease. Curr Opin Gastroenterol 2005: 21: 692.
3. Melamed D, Friedman A. Direct evidence for anergy in T lymphocytes tolerized by oral administration of ovalbumin. Eur J Immunol 1993: 23: 935.
4. Whitacre CC, Gienapp IE, Orosz CG, Bitar DM. Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy. J Immunol 1991: 147: 2155.
5. Chen Y, Inobe J, Marks R, Gonnella P, Kuchroo VK, Weiner HL. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 1995: 376: 177.
6. Gutgemann I, Fahrer AM, Altman JD, Davis MM, Chien YH. Induction of rapid T cell activation and tolerance by systemic presentation of an orally administered antigen. Immunity 1998: 8: 667.
7. Sayegh MH, Khoury SJ, Hancock WW, Weiner HL, Carpenter CB. Mechanisms of oral tolerance by MHC peptides. Ann N Y Acad Sci 1996: 778: 338.
8. Chen Y, Inobe J, Kuchroo VK, Baron JL, Janeway CA Jr, Weiner HL. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc Natl Acad Sci USA 1996: 93: 388.
9. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis. Science 1994: 265: 1237.
10. Trentham DE, Dynesius -Trentham RA, Orav EJ et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 1993: 261: 1727.
11. Bergerot I, Ploix C, Petersen J et al. A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci USA 1997: 94: 4610.
12. Ilan Y. Oral immune regulation toward disease-associated antigens: results of phase I clinical trials in Crohn's disease and chronic hepatitis. Ann N Y Acad Sci 2004: 1029: 286.
13. Carbone LD, Mc Kown K, Pugazhenthi M et al. Dosage effects of orally administered bovine type I collagen on immune function in patients with systemic sclerosis. Arthritis Rheum 2004: 50: 2713.
14. Mc Kown KM, Carbone LD, Kaplan SB et al. Lack of efficacy of oral bovine type II collagen added to existing therapy in rheumatoid arthritis. Arthritis Rheum 1999: 42: 1204.
15. Womer K, Meier-Kriesche H, Kaplan B. Graft and patient survival. In: M atthew M, W eir R eds. Medical Management of Kidney Transplantation. Philadelphia: Lippincott, Williams & Wilkins, 2005: 1.
16. Sayegh MH, Carpenter CB. Transplantation 50years later -progress, challenges, and promises. N Engl J Med 2004: 351: 2761.
17. Womer KL, Vella JP, Sayegh MH. Chronic allograft dysfunction: Mechanisms and new approaches to therapy. Semin Nephrol 2000: 20: 126.
18. Lee RS, Yamada K, Houser SL et al. Indirect recognition of allopeptides promotes the development of cardiac allograft vasculopathy. Proc Natl Acad Sci USA 2001: 98: 3276.
19. Womer KL, Stone JR, Murphy B, Chandraker A, Sayegh MH. Indirect allorecognition of donor class I and II major histocompatibility complex peptides promotes the development of transplant vasculopathy. J Am Soc Nephrol 2001: 12: 2500.
20. Vella JP, Ferreira M, Murphy B et al. Indirect allorecognition of MHC allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation 1997: 64: 795.
21. Poggio ED, Clemente M, Riley J et al. Alloreactivity in renal transplant recipients with and without chronic allograft nephropathy. J Am Soc Nephrol 2004: 15: 1952.
22. Baker RJ, Hernandez-Fuentes MP, Brookes PA, Chaudhry AN, Cook HT, Lechler RI. Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: Implications for the pathogenesis of chronic allograft nephropathy. J Immunol 2001: 167: 7199.
23. Ciubotariu R, Liu Z, Colovai AI et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1998: 101: 398.
24. Siva Sai KS, Smith MA, Poindexter NJ et al. Indirect recognition of donor HLA class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Transplantation 1999: 67: 1094.
25. Womer KL, Lee RS, Madsen JC, Sayegh MH. Tolerance and chronic rejection. Philos Trans R Soc Lond B Biol Sci 2001: 356: 727.
26. Womer KL, Sayegh MH, Auchincloss H Jr. Involvement of the direct and indirect pathways of allorecognition in tolerance induction. Philos Trans R Soc Lond B Biol Sci 2001: 356: 639.
27. Faria AM, Weiner HL. Oral tolerance: Therapeutic implications for autoimmune diseases. Clin Dev Immunol 2006: 13: 143.
28. Blanas E, Carbone FR, Allison J, Miller JF, Heath WR. Induction of autoimmune diabetes by oral administration of autoantigen. Science 1996: 274: 1707.